Role of immunohistochemical determination of Bcl-2 and p53 expression in identifying hormone receptors positive/Her 2 negative (Luminal-like) high-risk breast cancer patients

2020 ◽  
Vol 138 ◽  
pp. S94-S95
Author(s):  
G. Dajti ◽  
G. Cisternino ◽  
M. Serra ◽  
A. Pellegrini ◽  
S. Zanotti ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hormone Receptors ◽  
Breast Cancer Patients ◽  
P53 Expression ◽  
Her 2 ◽  
High Risk Breast Cancer ◽  
High Risk Breast ◽  
Risk Breast Cancer

scholarly journals Bisphosphonates and metastasis

2005 ◽  
Vol 8 (1) ◽  
Author(s):  
J. Lester ◽  
R. Coleman
Keyword(s):  
Breast Cancer ◽  
Bone Metastasis ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Control Pain ◽  
High Risk Breast Cancer ◽  
High Risk Breast ◽  
Risk Breast Cancer ◽  
Bone Physiology

Bone metastases frequently occur in advanced breast cancer patients and once incorporated into bone have profound effects on bone physiology. Bisphosphonates are potent inhibitors of osteoclastic function and are becoming increasingly important for the management of patients with breast cancer. They affect the ability of cancer cells to accelerate bone turnover and as a result control pain and reduce the risk of pathological fracture.Furthermore ongoing clinical trials are investigating the role of bisphosphonates as an adjuvant therapy in high-risk breast cancer patients with an aim to prevent bone metastasis.This article reviews the mechanisms of bone metastasis and will discuss present and future developments for the monitoring and treatment of metastatic bone disease.

Role of P53 and BCL-2 in high-risk breast cancer patients treated with adjuvant anthracycline-based chemotherapy

2000 ◽  
Vol 126 (12) ◽  
pp. 722-729 ◽  
Author(s):  
Marcella Mottolese ◽  
Maria Benevolo ◽  
Girolamo Del Monte ◽  
Simonetta Buglioni ◽  
Paola Papaldo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
High Risk ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
High Risk Breast Cancer ◽  
High Risk Breast ◽  
Risk Breast Cancer

Topoisomerase IIα Gene Amplification Predicts Favorable Treatment Response to Tailored and Dose-Escalated Anthracycline-Based Adjuvant Chemotherapy in HER-2/neu–Amplified Breast Cancer: Scandinavian Breast Group Trial 9401

2006 ◽  
Vol 24 (16) ◽  
pp. 2428-2436 ◽  
Author(s):  
Minna Tanner ◽  
Jorma Isola ◽  
Tom Wiklund ◽  
Björn Erikstein ◽  
Pirkko Kellokumpu-Lehtinen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Topoisomerase Iiα ◽  
Her 2 ◽  
Breast Group ◽  
High Risk Breast Cancer ◽  
High Risk Breast ◽  
Group Trial ◽  
Risk Breast Cancer

Purpose Amplification of the HER-2/neu and topoisomerase IIα (TOP2A) genes has been linked to the effects of anthracyclines. Their role in predicting the outcome of anthracycline-based adjuvant chemotherapy for breast cancer patients has remained controversial. Patients and Methods The present substudy of the Scandinavian Breast Group trial 9401, in which an epirubicin-based regimen (nine courses of tailored and dose-escalated fluorouracil, epirubicin, and cyclophosphamide [FEC]) was compared with three or four courses of standard FEC followed by bone marrow–supported high-dose chemotherapy (cyclophosphamide, thiotepa, and carboplatin), included high-risk breast cancer patients (with eight or more positive axillary lymph nodes or at least five nodes with additional poor prognostic indicators). Amplification of HER-2/neu was determined retrospectively in paraffin-embedded tumor tissue sections by chromogenic in situ hybridization. TOP2A was tested only in HER-2/neu–amplified tumors. Results HER-2/neu amplification alone, which was present in 32.7% of the tumors, was a strong prognostic factor for short relapse-free (P = .0034) and overall survival (P = .0008) but showed no direct association with treatment assignment. TOP2A coamplification, which was present in 37% of HER-2/neu–amplified tumors, was associated with better relapse-free survival in patients treated with tailored and dose-escalated FEC (hazard ratio [HR] = 0.45; P = .049). A statistical multivariate Cox's regression analysis confirmed the predictive significance of TOP2A coamplification (HR = 0.30; P = .020) in HER-2/neu–amplified tumors. There was no such association in patients with HER-2/neu–amplified tumors without TOP2A gene amplification. Conclusion Coamplification of HER-2/neu and TOP2A may define a subgroup of high-risk breast cancer patients who benefit from individually tailored and dose-escalated adjuvant anthracyclines.

Sign in / Sign up

Export Citation Format

Share Document